FDA Grants Breakthrough Device Designation to Quest’s Haystack MRD ctDNA Test
Quest Diagnostics has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its Haystack MRD® circulating tumour DNA (ctDNA) test. The designation covers the test’s use in detecting minimal residual disease (MRD) in patients with stage II colorectal cancer following surgery, helping to identify those who may benefit from adjuvant therapy.
The FDA programme is designed to speed up the development, review and availability of innovative devices that provide more effective treatment or diagnosis for serious or life-threatening conditions.
Haystack MRD is a highly sensitive liquid biopsy test that identifies tiny fragments of tumour-derived DNA in the bloodstream. By detecting residual or recurrent cancer earlier than imaging or other conventional methods, ctDNA MRD testing may allow clinicians to tailor treatment strategies and intervene before progression becomes clinically evident.
Quest introduced a laboratory-developed version of Haystack MRD in 2024 and is working to expand its use in both clinical practice and pharmaceutical research. The test has already been deployed in multiple clinical trials across the United States, Canada and Australia, and is in use at more than 75 cancer and academic centres.
The designation highlights the growing potential of ctDNA MRD testing in oncology, with research showing it can provide earlier insights into recurrence and treatment response across a range of solid tumours.